We are a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ocular surface diseases. Our lead product candidate, OC-01, a highly selective nicotinic acetylcholine receptors (nAChR) agonist, is being developed as a nasal spray to treat the signs and symptoms of dry eye disease (DED). The company is also developing other product candidates for diseases of the ocular surface and beyond.
Data Provided by Refinitiv. Minimum 15 minutes delayed.